ClinicalTrials.gg
CompletedNCT02176499Updated Jul 8, 2014

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

A Phase 3 interventional study of Telmisartan, low dose and Telmisartan, high dose in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
69th of 74
26 · median 381
Started
1999
with 8 others
Phase 3
43 of 122
1 open now
Registered
73rd of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 69th largest by enrollment of the 74 interventional ones that give a count, is one of 9 that started in 1999, is one of 43 in phase 3, and was the 73rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Study to compare the natriuretic effect of telmisartan to placebo in mild-to-moderate hypertensive patients on a controlled sodium diet as well as to explore the effects of telmisartan on norepinephrine, plasma renin activity (PRA), plasma aldosterone, urine potassium, creatinin, chloride, bicarbonate and uric acid excretion. Additionally it was assessed whether the natriuretic effect disappears after treatment when telmisartan is stopped. The effects of telmisartan on seated clinic blood pressure and the relationship between urine sodium loss and decrease in ambulatory blood pressure after the first dose were assessed descriptively. Assessment of safety was also considered.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild-to-moderate hypertension as defined by a morning mean diastolic blood pressure from ≥ 90 and ≤ 115 mmHg and a mean systolic blood pressure ≤ 200 mmHg after five minutes in the seated position at the end of three weeks of placebo run-in treatment
  • Male or female patients between 18 and 65 years of age, inclusive. Patients 60 to 65 years of age must have a screening 24-hour urine rate of ≥ 1 mL/sec
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ one year to start of screening)
  • women (last menstruation > one year from start of screening or have had a hysterectomy and oophorectomy)

    • Who have \< three months of stable estrogen replacement therapy at screening
    • Who will be on progesterone therapy at any time during the trial
  • Known or suspected secondary hypertension
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • (alanine aminotransferase) or AST (aspartate aminotransferase) greater than two times the upper limit of reference range
    • Serum creatinine greater than 2.3 mg/dL
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant
  • (New York Heart Association) functional class CHF (chronic heart failure) III-IV
  • Unstable angina, myocardial infarction or cardiac surgery within the preceding three months
  • Stroke within the preceding six months
  • PTCA (percutaneous transluminal coronary angioplasty) within the preceding three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, or other cardiac arrhythmias as determined by the clinical Investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with insulin-dependent and non-insulin-dependent diabetes mellitus
  • History of drug or alcohol dependency
  • Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, α-blockers, β-blockers, calcium channel antagonists, direct vasodilators at any time during the trial
  • Administration of other non-antihypertensive medications known to affect blood pressure (e.g., oral , MAO (monoamine oxidase) inhibitors, nitrates) at any time during the trial
  • Chronic administration of high doses of NSAIDS and aspirin (e.g., ibuprofen for rheumatoid arthritis and osteoarthritis in total daily dose in excess of 1600 mg, aspirin in excess of 2 Gm per day)
  • Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions
  • Clinically significant sodium depletion as defined by a serum sodium level less than 130 mEq/L
  • Clinically significant hyperkalemia as defined by a serum potassium level greater than 6.0 mEq/L. Clinically significant hypokalemia as defined by a serum potassium level less than 3.0 mEq/L
  • Patients receiving any therapy within one month of signing the form. Note that patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known to any component of telmisartan
  • Any other clinical condition which, in the opinion of the principal Investigator, would not allow safe completion of the protocol and safe administration of trial medication
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Telmisartan, low dose

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)

    Drug: Telmisartan, low dose · Drug: Placebo

  • Experimental
    Telmisartan, high dose

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)

    Drug: Telmisartan, high dose · Drug: Placebo

  • Placebo comparator
    Placebo

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)

    Drug: Placebo

Interventions

  • DrugTelmisartan, low dose
  • DrugTelmisartan, high dose
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Cumulative urinary sodium loss

    Time frame: 0-4, 4-8, 8-24 hours post-dose at baseline, day 0, day 7 and 0-24 hours post-dose on days 1-6

Secondary outcomes

  1. Cumulative urine sodium loss

    Time frame: 0-24 hours post-dose on days 8-13 and 0-4, 4-8, 8-24 hours post-dose on day 14

  2. Changes in body weight

    Time frame: 24 hours post-dose on days -28, -21 to -14, -7, -1, 0, 7, 14 and 22

  3. Changes in plasma norepinephrine

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  4. Changes in renin activity

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  5. Changes in aldosterone

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  6. Changes in urine potassium

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  7. Changes in creatinine chloride

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  8. Changes in bicarbonate

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  9. Changes in uric acid

    Time frame: Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22

  10. Cumulative urinary sodium gain during wash-out period

    Time frame: 0-24 hours post-dose on days from day 15 to 22

  11. Changes in seated clinic blood pressure

    Time frame: Baseline and day 14

  12. Changes in 24 hour ambulatory Blood Pressure (ABPM) after the first dose of telmisartan

    Time frame: Day 0

  13. Number of patients with adverse events

    Time frame: up to 50 days

  14. Number of patients with abnormal findings in physical examination

    Time frame: Baseline and day 22

  15. Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)

    Time frame: Baseline and day 22

  16. Number of patients with abnormal changes in laboratory parameters

    Time frame: Baseline and day 22

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 1999 and a primary completion of Jul 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2014
First posted
Jun 27, 2014
Start
Feb 1999
Primary completionActual
Jul 1999
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02176499
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Feb 1999
Primary completion
Jul 1999
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion